

Ref.: NLL/CS/2025-481

April 30, 2025

To

1. National Stock Exchange of India Limited
Listing Department,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai 400 051

Symbol: NECLIFE

2. BSE Limited
Corporate Relationship Department,
P J Towers, Dalal Street,
Mumbai 400 001

Scrip Code: 532649

Sub: Regulation 30 of the Securities and Exchange of Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, and as amended upto date.

Dear Sir/ Madam,

We are pleased to inform you that Unit II of Nectar Lifesciences Limited, located at Village Saidpura Tehsil Dera Bassi, District S. A. S. Nagar (Mohali), Punjab - 140507 – India, has received **Certification of Good Manufacturing Practices for Active Pharmaceutical Ingredients** vide File(s): 1329180/24-1 for Ceftazidime pentahydrate and Ceftriaxone disodium hemiheptahydrate (chemical synthesis and sterilization steps) from by Ministry of Health, National Health Surveillance Agency (ANVISA), Brazil.

This Certification is valid for two (2) years from April 28, 2025.

Kindly take the same on record.

Thanking you,

Yours faithfully,

For **Nectar Lifesciences Limited**

(Sanjaymohan Singh Rawat)

Company Secretary & Compliance Officer